One Edwards Way
305 articles about Edwards Lifesciences
Edwards’ HemoSphere Platform Receives Expanded Use Indication From Health Canada in Treatment of COVID-19 Patients
Edwards Lifesciences Corporation, the global leader in patient-focused innovations for structural heart disease and critical care monitoring, announced that Health Canada approved an expanded indication for use of the HemoSphere advanced monitoring platform in the treatment of COVID-19 patients.
As the American College of Cardiology (ACC) annual meeting opens in New Orleans this weekend, one of the big stories will undoubtedly be on the role of wrist sensors, such as the Apple Watch, in identifying heart rhythm problems. There will be other big stories, of course. Here’s a preview of jus...
Corvia Medical Enters Into Agreement With Edwards Lifesciences, The Global Leader In Structural Heart Innovation
Corvia Medical, Inc. announced it has entered into an agreement with Edwards Lifesciences.
Neovasc Inc. today announced that, pursuant to a settlement reached with Edwards Lifesciences PVT, Inc. and Edwards Lifesciences (Canada) Inc. (collectively, "Edwards"), the patent infringement action that Edwards had previously commenced in the Federal Court of Canada against Neovasc, Boston Scientific and Livanova, will be dismissed on a no-costs basis.
Delaware Court Rules Edwards Lifesciences Infringes Boston Scientific Patent
Bay Labs Announces Collaboration with Edwards Lifesciences to Utilize AI Software to Improve Heart Disease Detection
Bay Labs, a medical technology company at the forefront of applying artificial intelligence (AI) to cardiovascular imaging, announced today a collaboration with Edwards Lifesciences focused on improving the detection of heart disease.
Edwards Lifesciences Corporation will discuss the company's strategy for longer-term growth, provide an update on its technology pipeline and share its financial guidance during its annual investor conference today in Irvine, California.
The injunction will only become effective if Boston Scientific enforces it and provides a bond of €10 million.
Each year, Peter Drucker’s Drucker Institute generates its Management Top 250, evaluating companies based on what it calls five dimensions of corporate performance. Those five dimensions are Customer Satisfaction, Employee Engagement and Development, Innovation, Social Responsibility and Financia...
Nation's Top Heart Disease Patient Advocates Create Task Force Aimed at Improving Access, Research, and Awareness on Heart Valve Disease Detection and Treatment
The nation's leading heart disease patient advocates announced today the launch of the Heart Valve Disease Policy Task Force, a coalition of non-profit organizations uniting for a common voice in support of improved access, research, and awareness on heart valve disease detection and treatment.
Boston Scientific Corporation announced the U.K. Court of Appeal dismissed Edwards Lifesciences' appeal and upheld a prior court decision that Edwards' Sapien 3™ device infringes Boston Scientific patent EP (UK) 2 926 766 and that all claims of that patent are valid.
The Edwards CENTERA valve is repositionable and retrievable and can be delivered through a low-profile, 14-French, motorized delivery system.
Edwards Lifesciences, today reported financial results for the quarter ended December 31, 2017.
The Sapien 3 is a transcatheter aortic valve replacement designed to treat aortic stenosis.
12/18/2017Stifel's medical technology team recently visited with three top companies in their coverage universe.
Under the terms of the merger agreement, Edwards paid $100M in cash for Harpoon at closing on December 1, 2017 with a potential for up to an additional $150M in pre-specified milestone-driven payments.
Separately, the company also announced that in November it entered into an accelerated share repurchase agreement to acquire $150M of Edwards' common stock.
Edwards SAPIEN 3 Transcatheter Valve Demonstrates Significant Cost Savings Over Surgery In Intermediate Risk Patients
Results of the economic analysis were presented as a late-breaking clinical trial at the 29th TCT.